Trusted reliable news sources from around the web. We offer special news reports, topic news videos, and related content stories. Truly a birds eye view on news.
PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
DUBAI, United Arab Emirates, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Mutuum Finance (MUTM) continues to move through key roadmap milestones as the project enters a more advanced stage of development. Recent updates confirm that core security reviews are now complete, while participation across the project continues to expand. Together, these developments place Mutuum Finance at…
Ottawa, Jan. 02, 2026 (GLOBE NEWSWIRE) -- The materials informatics market size was estimated at USD 157.25 million in 2025 and is predicted to increase from USD 183.51 million in 2026 to approximately USD 736.71 million by 2035, expanding at a CAGR of 16.7% from 2026 to 2035. The urge for inventive materials and the…
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of StubHub Holdings, Inc. (NYSE: STUB) pursuant and/or traceable to the Registration Statement issued in connection with StubHub’s September 2025 initial public offering (the “IPO”), of the important January 23, 2026 lead…
London, UK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- XEROTECH LTD today launched CallGPT 6X, a productivity-focused AI platform that processes sensitive data within the user's browser before any information reaches AI providers. The platform combines client-side privacy filtering with unified access to six providers and over 20 models — including text, image generation, and text-to-speech…
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that as foreshadowed at the recent Annual General Meeting the Board will undertake a number of changes in line with the Company's evolution to a revenue-generating commercial company.
RSS
